Unknown PHASE2 NCT00030589

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma

Sponsor: Millennix

Conditions Lymphoma

Interventions UV light therapy bexarotene methoxsalen

Updated 5 times since 2017 Last updated: Dec 17, 2013 Started: Feb 28, 2001

A PHASE2 clinical study on Lymphoma, this trial is ongoing. The trial is conducted by Millennix and has accumulated 5 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Millennix

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Birmingham, United States , Boston, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Detroit, United States , East Setauket, United States , Houston, United States , Knoxville, United States and 7 more locations